Governments and drug companies must ensure healthcare access to new drugs, emphasizing human rights obligations.
The governance system proposed addresses drug pricing, aiming for improved equity in healthcare access.
Due diligence processes are critical for pharmaceutical companies to align with international human rights standards.
Enhancing access to costly drugs could significantly impact patients' rights globally.
Abstract
The obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write Trudo Lemmens and colleagues